Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna stated that mRNA technology has changed how clinical research into diseases is being conducted as well as how fast treatments are being tested and brought to market. The company released a ...

BOSTON--(BUSINESS WIRE)--Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, announced today preclinical data from its programmable mRNA ...

Strand Therapeutics, a Massachusetts Institute of Technology (MIT) spinout, has developed a new class of advanced mRNA molecules for more targeted and powerful treatments for cancer. The new class of ...

Messenger RNA (mRNA) vaccines have been crucial to containing and controlling the ongoing Covid-19 pandemic. Advances in self-amplifying RNA technology promise to make them even more cost ...

In the case of Strand’s lead anticancer treatment, the mRNA sequence contains elements that only switch translation on in the presence of microRNA biomarkers around tumors.

Strand’s therapy uses mRNA to make an inflammatory protein called interleukin-12, or IL-12, that causes immune cells to spring into action and unleash a cascade of events that kill cancer cells ...

BOSTON--(BUSINESS WIRE)--Strand Therapeutics, the world’s first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first ...

Scientists first begin by taking the genetic material of cancer cells and identifying the most mutated parts of the DNA – so-called neoantigens – before putting them in between a strand of mRNA.

In addition, Strand is advancing a broader pipeline powered by the company’s first-in-class cell-type specific mRNA engineering platform, including advancing STX-003, an intravenously ...

Over the last several days, the safety and efficacy of messenger RNA, or mRNA, vaccines have come under intense scrutiny. On Tuesday, the U.S. Food and Drug Administration announced plans to limit ...

BOSTON, May 28, 2025--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced exciting preliminary Phase 1 clinical data for its lead investigational candidate ...